Vineeta Agarwala
Bio + Health

Vineeta Agarwala



More About Vineeta

Vineeta Agarwala, MD, PhD is a General Partner at Andreessen Horowitz (a16z) where she leads investments for the firm’s bio + health fund across biotech, life sciences software, and digital health, with a focus on companies leveraging unique technologies and datasets to advance drug development, personalized medicine, and innovation in patient care delivery.

Prior to joining a16z, Vineeta held many different roles in the healthcare space: as a physician taking care of patients; as an operator at healthtech startups; and as a venture investor on the GV (Google Ventures) life sciences team. She has been a data scientist; a management consultant for biotech, pharmaceutical, and medical device clients at McKinsey & Co; and a Director of Product Management at Flatiron Health (acquired by Roche), where she led the company’s partnership with Foundation Medicine to integrate real-world clinical and genomic data into national-scale data products to accelerate research and development in oncology. She has conducted academic research at Cold Spring Harbor Laboratory, Lawrence Livermore National Laboratory, and the Broad Institute, where she did graduate work in computational biology and human genetics.

Vineeta holds a B.S. in biophysics from Stanford University, and MD and PhD degrees from Harvard Medical School / MIT. She completed her clinical residency at Stanford, and is board certified in internal medicine. Vineeta continues to see patients at Stanford as an adjunct clinical professor in the Division of Primary Care and Population Health.

Vineeta serves on several portfolio company boards, including Amber Bio, BigHat Biosciences, Gate Bio, GC Therapeutics, Orbital Therapeutics, Rezo Therapeutics, Memora Health, Pearl Health, Pomelo Care, Thyme Care, and Waymark.

Latest Content

  • Dark Genome Hunting with Rosana Kapeller and Marty Taylor
    Vineeta Agarwala, Bryan Faust, Rosana Kapeller, Kris Tatiossian, Marty Taylor, and Olivia Webb

    Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.

  • Virtual Data Rooms: The Unsung Hero of Biotech Financing
    Bryan Faust, Becky Pferdehirt, and Vineeta Agarwala

    The biotech industry is built on one of the cleanest go-to-market strategies in existence: if you make a safe drug that really works, patients are likely to receive it and payors are likely to pay for it. But how can biotech teams effectively communicate to investors and partners how they will, with each round of financing, incrementally reduce the risks of discovering and developing successful new drugs?

  • Gate Unveiling with Jordi Mata-Fink
    Vineeta Agarwala, Jordi Mata-Fink, Ben Portney, Kris Tatiossian, and Olivia Webb

    Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed "molecular gates."

  • Investing in Gate Bioscience
    Vineeta Agarwala

    While most small molecule drugs bind and inhibit the disease-causing activity of their (typically intracellular) protein targets, Gate Bio instead attacks harmful extracellular proteins by eliminating them at their very root: right where they are produced and secreted from the cell.

  • Greg Verdine, Bio + Health Venture Partner
    Vineeta Agarwala and Jorge Conde

    As we strive to find and support the most ambitious life sciences founders, we also work to connect these founders with exceptional advisors who have traveled the journey before.

Load More

Select Investments

Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments. A list of investments made by funds managed by a16z is available here:

go to top